S Danson
Overview
Explore the profile of S Danson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, et al.
Ann Oncol
. 2018 Nov;
30(2):317-324.
PMID: 30428063
Background: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most...
2.
Hardy-Werbin M, Arpi O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, et al.
Oncoimmunology
. 2018 Jan;
7(2):e1395125.
PMID: 29308329
Small-cell lung cancer (SCLC) is often associated with paraneoplastic syndromes. To assess the role of anti-neuronal autoantibodies (NAAs) as biomarkers of treatment outcome, we assessed NAAs in serial samples from...
3.
Gupta A, Love S, Schuh A, Shanyinde M, Larkin J, Plummer R, et al.
Ann Oncol
. 2014 Feb;
25(5):968-74.
PMID: 24567366
Background: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has...
4.
Wheatley-Price P, Blackhall F, Lee S, Ma C, Ashcroft L, Jitlal M, et al.
Ann Oncol
. 2010 Mar;
21(10):2023-2028.
PMID: 20332134
Background: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis...
5.
Boss D, Schwartz G, Middleton M, Amakye D, Swaisland H, Midgley R, et al.
Ann Oncol
. 2009 Oct;
21(4):884-894.
PMID: 19825886
Background: AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438...
6.
Danson S, Dean E, Dive C, Ranson M
Curr Cancer Drug Targets
. 2008 Jan;
7(8):785-94.
PMID: 18220537
The avoidance of apoptosis is one of the hallmarks of cancer cells. In addition, failure to induce apoptosis by anticancer agents, either due to limitations of the drug or the...
7.
Danson S, Ranson M, Denneny O, Cummings J, Ward T
Cancer Chemother Pharmacol
. 2007 Mar;
60(6):851-61.
PMID: 17333193
Purpose: RH1 is a novel anticancer agent with potent DNA-cross linking activity. RH1 has the potential to be activated within tumors over expressing NQO1, giving maximal antitumour activity with reduced...
8.
9.
Baka S, Ranson M, Lorigan P, Danson S, Linton K, Hoogendam I, et al.
Eur J Cancer
. 2005 Jul;
41(11):1547-50.
PMID: 16026691
Rubitecan (RFS2000, 9 nitrocamptothecin,) is a new oral topoisomerase I inhibitor. We report a phase II, single-arm, open-label study of RFS2000 as first line treatment for non-small cell lung cancer...
10.
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al.
Lung Cancer
. 2004 Dec;
47(1):69-80.
PMID: 15603856
Purpose: Gemcitabine-platinum combination activity has been clearly established in a number of phase II studies. It has also been compared against other combinations in many phase III trials. It is...